| heart failure | versus placebo or control No demonstrated result for efficacy Flosequinan inferior to placebo in terms of Vertigo in REFLECT, 1993 | 4 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| Cowley, 1993 | Flosequinan vs placebo | | | Total mortality 1.11 [0.07; 17.37] Sudden death 1.11 [0.07; 17.37] Worsening heart failure (requiring intervention) 4.44 [0.51; 38.68] | | FACET, 1993 | Flosequinan vs placebo | | | Total mortality 1.12 [0.44; 2.88] Sudden death 0.00 [0.00; NaN] Worsening heart failure (requiring intervention) 1.19 [0.59; 2.42] Arrhythmia 2.77 [0.82; 9.29] Vertigo 1.62 [0.76; 3.47] | | REFLECT, 1993 | Flosequinan vs placebo | | Vertigo 2.80 [1.04; 7.54] | Total mortality 3.76 [0.80; 17.66] Myocardial infarction (fatal & non fatal) 1.61 [0.28; 9.44] Sudden death 2.69 [0.53; 13.52] Worsening heart failure (requiring intervention) 0.51 [0.24; 1.07] Arrhythmia ∞ [NaN; ∞] | | REFLECT II, 1991 | Flosequinan vs placebo | | | Total mortality 1.11 [0.39; 3.10] |
| Trial | Treatments | Patients | Method |
|---|
| Cowley, 1993 | Flosequinan 125mg/d (n=64) vs. placebo (n=71) | NYHA II, III | double blind Parallel groups Sample size: 64/71 Primary endpoint: FU duration: 4 months | | FACET, 1993 | Flosequinan 100 and 150 mg/d (n=212) vs. placebo (n=110) | NYHA II, III | double blind Parallel groups Sample size: 212/110 Primary endpoint: FU duration: 4 months | | REFLECT, 1993 | Flosequinan 100mg/d (n=93) vs. placebo (n=100) | NYHA II,III | double blind Parallel groups Sample size: 93/100 Primary endpoint: Exercise tolerance FU duration: 3 months | | REFLECT II, 1991 | Flosequinan 100, 150 mg/d (n=207) vs. (n=104) | NYHA II-IV | double blind Parallel groups Sample size: 207/104 Primary endpoint: Exercise tolerance FU duration: 3 months |
|
